Top

Published in:

01-02-2020 | Kidney Transplantation | Original article

Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation

Authors: Osamu Soma, Shingo Hatakeyama, Tohru Yoneyama, Mitsuru Saito, Hideo Sasaki, Yuki Tobisawa, Daisuke Noro, Yuichiro Suzuki, Masakazu Tanaka, Shin-Ichiro Nishimura, Hiroshi Harada, Hideki Ishida, Kazunari Tanabe, Shigeru Satoh, Chikara Ohyama

Published in: Clinical and Experimental Nephrology | Issue 2/2020

Abstract

Background

To evaluate whether serum N-glycan profile can be used as a diagnostic marker of graft rejection after living-donor kidney transplants (KT).

Methods

We retrospectively examined 174 KT recipients at five medical centers. N-Glycan levels were analyzed in postoperative serum samples using glycoblotting combined with mass spectrometry. We developed an integrated score to predict graft rejection based on a combination of age, gender, immunological risk factors, and serum N-glycan levels at post-KT day D1 and D7. Rejection-free survival rates stratified by the sum of integrated scores (D1 + D7) were evaluated using Kaplan–Meier curves.

Results

Of 174, 52 showed graft rejection (Rejection-pos. group) and 122 recipients did not show graft rejection (Rejection-neg. group). The integrated scores were significantly higher in the Rejection-pos. group than those of the Rejection-neg. group. Area-under-curve (AUC) value of integrated scores at post-KT D1, and D7 were 0.84 and 0.84, respectively. The sum of integrated scores (D1 + D7) ≥ 0.50 identified graft rejection with 81% sensitivity and 80% specificity; with an AUC value of 0.87. Recipients with higher sum of integrated scores (D1 + D7 ≥ 0.5) had significantly shorter rejection-free survival than those with lower scores.

Conclusion

Evaluation of serum N-glycosylation profiles can identify recipients who are prone to rejection.

Available only for authorised users

Okumi M, Unagami K, Kakuta Y, Ochi A, Takagi T, Ishida H, et al. Elderly living donor kidney transplantation allows worthwhile outcomes: the Japan Academic Consortium of Kidney Transplantation study. Int J Urol. 2017;24(12):833–40. https://doi.org/10.1111/iju.13443.CrossRefPubMed

Kubota Y, Hatakeyama S, Narita I, Shimada M, Hashimoto Y, Ohyama C. Clinical impact of glomerular basement membrane thickness on post-donation renal function in living donors. Int J Urol. 2019;26(2):309–11. https://doi.org/10.1111/iju.13850.CrossRefPubMed

Kusaka M, Kubota Y, Takahashi H, Sasaki H, Kawai A, Takenaka M, et al. Warm ischemic time as a critical risk factor of graft failure from donors after cardiac death: a single-center experience over three decades in the Kidney Donor Profile Index/Kidney Donor Risk Index era in Japan. Int J Urol. 2019;26(2):247–52. https://doi.org/10.1111/iju.13851.CrossRefPubMed

Nishioka T, Yoshimura N, Ushigome H, Watarai Y, Nishimura K, Akioka K, et al. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: a Japanese multicenter study. Int J Urol. 2018;25(2):141–5. https://doi.org/10.1111/iju.13476.CrossRefPubMed

Hamano I, Hatakeyama S, Yamamoto H, Fujita T, Murakami R, Shimada M, et al. Impact of distance between donor and recipient hospitals on cadaveric kidney transplantation outcomes. Clin Exp Nephrol. 2019;23(6):807–13. https://doi.org/10.1007/s10157-019-01710-z.CrossRefPubMed

Ma MK, Law HK, Tse KS, Chan KW, Chan GC, Yap DY, et al. Non-invasive assessment of kidney allograft fibrosis with shear wave elastography: a radiological-pathological correlation analysis. Int J Urol. 2018;25(5):450–5. https://doi.org/10.1111/iju.13536.CrossRefPubMed

Takeuchi A, Kato K, Akashi K, Eto M. Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy. Int J Urol. 2018;25(2):112–20. https://doi.org/10.1111/iju.13474.CrossRefPubMed

Kakuta Y, Imamura R, Okumi M, Horio M, Isaka Y, Ichimaru N, et al. Assessment of renal function in living kidney donors before and after nephrectomy: a Japanese prospective, observational cohort study. Int J Urol. 2019;26(4):499–505. https://doi.org/10.1111/iju.13923.CrossRefPubMed

Hatakeyama S, Fujita T, Murakami R, Suzuki Y, Sugiyama N, Yamamoto H, et al. Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: a single-center experience. Transplant Proc. 2014;46(2):445–8. https://doi.org/10.1016/j.transproceed.2013.09.036.CrossRefPubMed

10.

Maenosono R, Unagami K, Kakuta Y, Furusawa M, Okumi M, Azuma H, et al. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation. Int J Urol. 2019. https://doi.org/10.1111/iju.14108.CrossRefPubMed

11.

Tasaki M, Saito K, Nakagawa Y, Imai N, Ito Y, Yoshida Y, et al. Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors. Int J Urol. 2019. https://doi.org/10.1111/iju.14118.CrossRefPubMed

12.

Erpicum P, Hanssen O, Weekers L, Lovinfosse P, Meunier P, Tshibanda L, et al. Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples. Clin Kidney J. 2017;10(1):106–15. https://doi.org/10.1093/ckj/sfw077.CrossRefPubMed

13.

Malard-Castagnet S, Dugast E, Degauque N, Pallier A, Soulillou JP, Cesbron A, et al. Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection. Hum Immunol. 2016;77(11):1076–83. https://doi.org/10.1016/j.humimm.2015.10.021.CrossRefPubMed

14.

Noro D, Yoneyama T, Hatakeyama S, Tobisawa Y, Mori K, Hashimoto Y, et al. Serum aberrant N-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant. Int J Mol Sci. 2017;18(8):1731. https://doi.org/10.3390/ijms18081731.CrossRefPubMedCentral

15.

Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J. 1999;18(6):1516–25. https://doi.org/10.1093/emboj/18.6.1516.CrossRefPubMedPubMedCentral

16.

Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 2011;30(15):3173–85. https://doi.org/10.1038/emboj.2011.215.CrossRefPubMedPubMedCentral

17.

Tsuboi S, Hatakeyama S, Ohyama C, Fukuda M. Two opposing roles of O-glycans in tumor metastasis. Trends Mol Med. 2012;18(4):224–32. https://doi.org/10.1016/j.molmed.2012.02.001.CrossRefPubMedPubMedCentral

18.

Hatakeyama S, Amano M, Tobisawa Y, Yoneyama T, Tsuchiya N, Habuchi T, et al. Serum N-glycan alteration associated with renal cell carcinoma detected by high throughput glycan analysis. J Urol. 2014;191(3):805–13. https://doi.org/10.1016/j.juro.2013.10.052.CrossRefPubMed

19.

Ishibashi Y, Tobisawa Y, Hatakeyama S, Ohashi T, Tanaka M, Narita S, et al. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer. Prostate. 2014;74(15):1521–9. https://doi.org/10.1002/pros.22869.CrossRefPubMed

20.

Oikawa M, Hatakeyama S, Yoneyma T, Tobisawa Y, Narita T, Yamamoto H, et al. Significance of serum N-glycan profiling as a diagnostic biomarker in urothelial carcinoma. Eur Urol Focus. 2018;4(3):405–11. https://doi.org/10.1016/j.euf.2016.11.004.CrossRefPubMed

21.

Narita T, Hatakeyama S, Yoneyama T, Narita S, Yamashita S, Mitsuzuka K, et al. Clinical implications of serum N-glycan profiling as a diagnostic and prognostic biomarker in germ-cell tumors. Cancer Med. 2017;6(4):739–48. https://doi.org/10.1002/cam4.1035.CrossRefPubMedPubMedCentral

22.

Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, et al. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun. 2014;448(4):390–6. https://doi.org/10.1016/j.bbrc.2014.04.107.CrossRefPubMed

23.

Ishikawa T, Yoneyama T, Tobisawa Y, Hatakeyama S, Kurosawa T, Nakamura K, et al. An automated micro-total immunoassay system for measuring cancer-associated α2,3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis. Int J Mol Sci. 2017;18(2):470. https://doi.org/10.3390/ijms18020470.CrossRefPubMedCentral

24.

Tanaka T, Yoneyama T, Noro D, Imanishi K, Kojima Y, Hatakeyama S, et al. Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas. Int J Mol Sci. 2017;18(12):2632. https://doi.org/10.3390/ijms18122632.CrossRefPubMedCentral

25.

Hatakeyama S, Amano M, Tobisawa Y, Yoneyama T, Tsushima M, Hirose K, et al. Serum N-glycan profiling predicts prognosis in patients undergoing hemodialysis. Sci World J. 2013;2013:268407. https://doi.org/10.1155/2013/268407.CrossRef

26.

Haas M. The revised (2013) banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant. 2016;16(5):1352–7. https://doi.org/10.1111/ajt.13661.CrossRefPubMed

27.

Nara M, Komatsuda A, Numakura K, Saito M, Inoue T, Niioka T, et al. Quantification of interstitial fibrosis in renal allografts and clinical correlates of long-term graft function. Am J Nephrol. 2017;46(3):187–94. https://doi.org/10.1159/000479983.CrossRefPubMed

28.

Takeuchi M, Amano M, Kitamura H, Tsukamoto T, Masumori N, Hirose K, et al. N- and O-glycome analysis of serum and urine from bladder cancer patients using a high-throughput glycoblotting method. J Glycom Lipidom. 2013;3(108):1–8. https://doi.org/10.4172/2153-0637.1000108.CrossRef

29.

Uchida J, Kosoku A, Naganuma T, Tanaka T, Nakatani T. Latest insights on ABO-incompatible living-donor renal transplantation. Int J Urol. 2019. https://doi.org/10.1111/iju.14109.CrossRefPubMed

30.

Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015;125(11):4160–70. https://doi.org/10.1172/jci82695.CrossRefPubMedPubMedCentral

31.

Hess C, Winkler A, Lorenz AK, Holecska V, Blanchard V, Eiglmeier S, et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clin Invest. 2013;123(9):3788–96. https://doi.org/10.1172/jci65938.CrossRefPubMedPubMedCentral

32.

Amano M, Yamaguchi M, Takegawa Y, Yamashita T, Terashima M, Furukawa J, et al. Threshold in stage-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation. Mol Cell Proteom. 2010;9(3):523–37. https://doi.org/10.1074/mcp.M900559-MCP200.CrossRef

33.

Dijk van W, Havenaar EC, Brinkman-van der Linden EC. Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Glycoconj J. 1995;12(3):227–33.CrossRef

Title: Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation
Authors: Osamu Soma
Shingo Hatakeyama
Tohru Yoneyama
Mitsuru Saito
Hideo Sasaki
Yuki Tobisawa
Daisuke Noro
Yuichiro Suzuki
Masakazu Tanaka
Shin-Ichiro Nishimura
Hiroshi Harada
Hideki Ishida
Kazunari Tanabe
Shigeru Satoh
Chikara Ohyama
Publication date: 01-02-2020
Publisher: Springer Singapore
Keywords: Kidney Transplantation
Kidney Transplantation
Kidney Transplantation
Kidney Transplantation
Kidney Transplantation
Kidney Transplantation
Biomarkers
Published in: Clinical and Experimental Nephrology / Issue 2/2020
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-019-01820-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Effects of dietary protein intake on renal outcome and mortality in patients with advanced diabetic nephropathy

Sleep debt and prevalence of proteinuria in subjects with short sleep duration on weekdays: a cross-sectional study

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study

Kidney Disease: Improving Global Outcomes in neonates with acute kidney injury after cardiac surgery

Role of A20/TNFAIP3 deficiency in lupus nephritis in MRL/lpr mice

Two-step treatment model for the adult patients with an obstructed kidney functioning below 10% of its capacity: a pilot study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page